Literature DB >> 2386617

Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS.

I H Grant1, J W Gold, M Rosenblum, D Niedzwiecki, D Armstrong.   

Abstract

Central nervous system (CNS) toxoplasmosis is an important infectious complication of AIDS which requires prolonged treatment. Most cases occur in patients with serologic evidence of prior exposure and therefore appear to result from reactivation of a previously acquired infection. Antibody to Toxoplasma gondii was found in 130 out of 411 patients with AIDS (32%). Of these, CNS toxoplasmosis developed in 31 (24%). By survival analysis, the estimated probability of ever developing CNS infection in antibody-positive individuals was 28%, occurring in 26% of patients within 2 years of the onset of AIDS. All patients with HIV infection should be tested for antibody to T. gondii and monitored for any neurologic change. Methods of prophylaxis for CNS toxoplasmosis in these high-risk patients need to be developed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386617

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  50 in total

1.  Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus.

Authors:  C Leport; J Franck; G Chene; F Derouin; J L Ecobichon; S Pueyo; J M Miro; B J Luft; P Morlat; H Dumon
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Understanding Toxoplasmosis in the United States Through "Large Data" Analyses.

Authors:  Joseph Lykins; Kanix Wang; Kelsey Wheeler; Fatima Clouser; Ashtyn Dixon; Kamal El Bissati; Ying Zhou; Christopher Lyttle; Andrey Rzhetsky; Rima McLeod
Journal:  Clin Infect Dis       Date:  2016-06-26       Impact factor: 9.079

3.  Food Safety Knowledge, Beliefs and Behavior of Persons with AIDS: A Multicenter Study.

Authors:  Mark S Dworkin; Caryn E Peterson; Weihua Gao; Angel Mayor; Robert Hunter; Edna Negron; Alison Fleury; C Lynn Besch
Journal:  Food Prot Trends       Date:  2013-01-01

Review 4.  Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.

Authors:  L W Cheever; R E Chaisson; J E Gallant
Journal:  West J Med       Date:  1996 Jul-Aug

5.  Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS.

Authors:  R F Miller; M A Hall-Craggs; D C Costa; N S Brink; F Scaravilli; S B Lucas; I D Wilkinson; P J Ell; B E Kendall; M J Harrison
Journal:  Sex Transm Infect       Date:  1998-08       Impact factor: 3.519

6.  Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade.

Authors:  Rajarshi Bhadra; Jason P Gigley; Louis M Weiss; Imtiaz A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

7.  Seroprevalence of Toxoplasma IgG Antibodies in HIV Positive Patients in and Around Khammam, Telangana State.

Authors:  Basavaraju Anuradha; Chilupuri Preethi
Journal:  J Clin Diagn Res       Date:  2014-09-20

8.  Evaluation of Toxoplasma gondii soluble, whole and excretory/secretary antigens for diagnosis of toxoplasmosis by ELISA test.

Authors:  S Pishkari; S Shojaee; H Keshavarz; M Salimi; M Mohebali
Journal:  J Parasit Dis       Date:  2016-06-03

9.  Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine.

Authors:  S Köppen; T Grünewald; G Jautzke; J Gottschalk; H D Pohle; B Ruf
Journal:  Clin Investig       Date:  1992-06

10.  Sero-prevalence of latent Toxoplasma gondii infection among HIV-infected and HIV-uninfected people in Addis Ababa, Ethiopia: A comparative cross-sectional study.

Authors:  Techalew Shimelis; Mekashaw Tebeje; Endale Tadesse; Belete Tegbaru; Ashenafi Terefe
Journal:  BMC Res Notes       Date:  2009-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.